このエントリーをはてなブックマークに追加
ID 48266
JaLCDOI
FullText URL
Author
Utsumi, Hiroya
Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group
Abstract
Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17オ and 34オ (hazard ratio, 0.57;95オ confidence interval, 0.18‒1.81;p=0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.
Keywords
cabergoline
levodopa
Parkinsonʼs disease
motor complications
Amo Type
Original Article
Published Date
2012-04
Publication Title
Acta Medica Okayama
Volume
volume66
Issue
issue2
Publisher
Okayama University Medical School
Start Page
163
End Page
170
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2012 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT